BCP
GILD icon

Blackhawk Capital Partners’s Gilead Sciences GILD Stock Holding History

Blackhawk Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,185
Closed -$438K – 157
2018
Q2 		$438K Buy
6,185
+95
+2% +$6.71K 0.5% 55
2018
Q1 		$459K Sell
6,090
-6,400
-51% -$509K 0.39% 60
2017
Q4 		$895K Buy
+12,490
New +$948K 0.77% 42

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Blackhawk Capital Partners's GILD Position: Q3 2018 in Review

Blackhawk Capital Partners sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 6,185 shares — an estimated $438K sold.

Blackhawk Capital Partners first reported a position in GILD in Q4 2017 and held it in 3 quarters. The position peaked at $895K in Q4 2017. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

  • Blackhawk Capital Partners reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
  • Blackhawk Capital Partners sold 6,185 Gilead Sciences shares in Q3 2018, an estimated $438K.
  • Blackhawk Capital Partners first reported a position in Gilead Sciences in Q4 2017 and held it in 3 quarters.
  • Blackhawk Capital Partners's Gilead Sciences position peaked at $895K in Q4 2017.
  • 1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Blackhawk Capital Partners's 13F filing for Q3 2018, filed 13 Nov 2018.